Page 2 of 2
The search for validated biomarkers in the face of biosystems complexity. Spring 05By Professor Ian Humphery-Smith and Will Dracup As the pharmaceutical industry is all too well aware, the genomics and postgenomic sciences have delivered an excessive number of drug targets – few of which have been well validated. I...
|
Overview of biomarkers in disease, drug discovery and development. Spring 05By Professor Stephen Naylor The pharmaceutical industry and the healthcare sector are both confronted with expensive technological innovation, escalating costs and pointed questions about productivity and efficiency...
|
EXPERIMENTAL MEDICINE developing biomarkers in early discovery to bridge preclinical and clinical development. Winter 04By Dr Robert Dix In today’s pharmaceutical research and development environment a major problem is the transition of too many drugs to later stages of development with insufficient and/or inadequate inf...
|
Systems biology, information, disease and drug discovery. Winter 04By Professor Stephen Naylor Pharmaceutical companies are confronted with an urgent need to increase their lead compound and clinical candidate portfolios and to satisfy market demands for continued innovation and re...
|
METABONOMICS a generic platform for the investigation of drug toxicity, altered gene function and disease processes. Summer 04By Professor Jeremy K. Nicholson Metabonomics can offer one of the most complete solutions to tackling one of the pharmaceutical industry’s biggest problems – attrition.This article discusses the scope and uses of me...
|
precise phenotypic anchoring for drug target identification, validation and biomarker discovery using an advanced SYSTEMS BIOLOGY approach. Summer 04By Dr Peter C. Johnson and Dr Alan J. Higgins The pharmaceutical industry has not seen the hoped-for productivity gains from the various omics datastreams over the last decade.This article discusses how systems biology can exploit th...
|
Page 2 of 2
